Keyphrases
Multiple Sclerosis
100%
Disease-modifying Therapy
100%
Pharmacogenetics
100%
Glatiramer Acetate
100%
Multiple Sclerosis Treatment
42%
C-C Chemokine Receptor Type 5 (CCR5)
28%
Non-responders
28%
Epigenetic Biomarkers
28%
Pharmacogenetic Study
28%
IFNAR1
28%
Composite Biomarkers
28%
Transforming Growth factor-β1 (TGF-β1)
14%
Treatment Choice
14%
Mode of Action
14%
Genetic Variants
14%
Neurodegenerative Diseases
14%
Clinical Criteria
14%
Treatment Response
14%
Polymorphic Variants
14%
CCR5 Gene
14%
Autoimmune
14%
Immune-related Genes
14%
Should Be Given
14%
Therapy Response
14%
Therapy Choice
14%
Pharmacological Analysis
14%
DRB1 Gene
14%
Bioinformatics Algorithms
14%
Long-term Medication
14%
CTLA-4 Gene
14%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Multiple Sclerosis
100%
Pharmacogenetics
100%
Glatiramer
100%
Biological Marker
62%
Degenerative Disease
12%
Immunology and Microbiology
Multiple Sclerosis
100%
Pharmacogenetics
100%
Glatiramer Acetate
100%
CCR5
50%
Pharmacogenetic Testing
50%
Genetic Variability
16%
Immune Response Gene
16%
Neuroscience
Multiple Sclerosis
100%
Glatiramer Acetate
100%
CCR5
50%
Neurodegenerative Disorder
16%
Cytotoxic T Lymphocyte Antigen 4
16%
Immune Response Gene
16%